|
|
|
|
Office Locations:
|
11 Times Square, Suite 1500A
New York, NY 10036
Phone: 646-491-7988
| |
|
|
|
|
|
|
Electronics & Advanced Materials
Information Technology
Life Sciences & Healthcare
|
|
|
|
Digitalis is a venture capital firm that creates and invests in fundamental new ideas to address complex health problems. Target sectors include: Data Architecture, Physical Computing, Chemical Measurement, Biology as Engineering, Bioelectronics, and Precision Medicine.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Amit Bansal | |
| |
Partner | |
| Drew Taylor | |
| |
Partner | |
| Geoffrey W. Smith | |
| |
Founder and Managing Partner | |
| Steve Allen | |
| |
Partner | |
| Victoria Perweiler | |
| |
Venture Partner | |
|
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
10/23/2024
|
Alpha-9 Oncology
|
MA
|
$175,000,000
|
Series C
|
10/18/2024
|
Terray Therapeutics
|
CA
|
$120,000,000
|
Series B
|
10/07/2024
|
Judo Bio
|
MA
|
$100,000,000
|
Seed and Series A
|
08/04/2024
|
GRO Biosciences
|
MA
|
$60,000,000
|
Series B
|
07/16/2024
|
Cardurion Pharmaceuticals
|
MA
|
$260,000,000
|
Series B
|
05/21/2024
|
Expressable
|
TX
|
$26,000,000
|
Series B
|
03/07/2024
|
MoeGo
|
CA
|
$24,000,000
|
Series A
|
01/08/2024
|
Gallant Therapeutics
|
CA
|
$15,000,000
|
Series A
|
|
|
|
|
|
|
|
